Actinogen Medical (ASX:ACW) Cash-to-Debt : 254.93 (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Actinogen Medical Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Actinogen Medical's cash to debt ratio for the quarter that ended in Dec. 2023 was 254.93.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Actinogen Medical could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Actinogen Medical's Cash-to-Debt or its related term are showing as below:

ASX:ACW' s Cash-to-Debt Range Over the Past 10 Years
Min: 12.92 Med: No Debt Max: No Debt
Current: 254.93

During the past 13 years, Actinogen Medical's highest Cash to Debt Ratio was No Debt. The lowest was 12.92. And the median was No Debt.

ASX:ACW's Cash-to-Debt is ranked better than
83.18% of 1492 companies
in the Biotechnology industry
Industry Median: 6.85 vs ASX:ACW: 254.93

Actinogen Medical Cash-to-Debt Historical Data

The historical data trend for Actinogen Medical's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Actinogen Medical Cash-to-Debt Chart

Actinogen Medical Annual Data

Trend

Jun13

Jun14

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

12.92

56.87

99.21

97.24

Actinogen Medical Semi-Annual Data
	Dec13	Jun14	Dec14	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															110.05	99.21	114.05	97.24	254.93

Competitive Comparison of Actinogen Medical's Cash-to-Debt

For the Biotechnology subindustry, Actinogen Medical's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Actinogen Medical's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actinogen Medical's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Actinogen Medical's Cash-to-Debt falls into.

Actinogen Medical Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Actinogen Medical's Cash to Debt Ratio for the fiscal year that ended in Jun. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	8.46	/	(0.087	+	0)
	=	97.24

Actinogen Medical's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	11.472	/	(0.045	+	0)
	=	254.93

Actinogen Medical (ASX:ACW) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Actinogen Medical Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Actinogen Medical's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Actinogen Medical (ASX:ACW) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actinogen Medical Ltd (ASX:ACW) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

3AC:Germany

Address

109 Pitt Street, Level 9, Suite 901, Sydney, NSW, AUS, 2000

Website

https://www.actinogen.com.au

Actinogen Medical Ltd is a biotechnology company. The company develops drugs for Alzheimer's disease and the cognitive decline associated with other neurological diseases. Geographically, it operates and derives revenue from Australia. It has developed a product Xanamem.

Actinogen Medical (ASX:ACW) Headlines

From GuruFocus

Accuride Corporation: Earnings Report For Q2 2014

By Black Iguana Nitish • 10-13-2014

Stocks That Are Making A Good Come Back

By reports.droy reports.droy • 03-10-2015